{"entity":{"id":"nct07464327","kind":"trial","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","aka":[],"tldr":"A phase 3 trial of HS-20093 and docetaxel in lung cancer, run by Hansoh BioMedical R&D Company, not yet recruiting.","summary":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations is a phase 3, randomised interventional study registered as NCT07464327 by Hansoh BioMedical R&D Company, with a registry enrolment figure of 450 participants, started 2026-03-31 and due to reach its primary completion in 2028-12-31. Interventions recorded: HS-20093; Docetaxel. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR); Overall survival (OS). Lung eligibility wording from the registry: \"Previously treated patients with histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07464327","url":"https://clinicaltrials.gov/study/NCT07464327"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["hs-20093","docetaxel"],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07464327","phase":"3","setting":"A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","sponsor":"Hansoh BioMedical R&D Company","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07464327/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}